

Indian Journal of Pharmaceutical Sciences

Scientific Publication of the Indian Pharmaceutical Association

Indexed in Ind MED, EMBASE/Excerpta Medica, International Pharmaceutical Abstracts, Chemical Abstracts.

Volume 70

Number 1

January-February 2008

CONTENTS

REVIEW ARTICLES

A Decision Tree for Rapid Quality Assurance and Control of Rifampicin-Containing Oral Dosage Forms for Global Distribution for Tuberculosis Treatment

Y. ASHOKRAJ, SHRUTIDEVI AGRAWAL AND R. PANCHAGNULA 1-4
SWATI RAWAT, SUDHA VENGURLEKAR, B. RAKESH, S. JAIN, G. SRIKARTI 5-10

RESEARCH PAPERS

In vivo Evaluation of Single Dose Tetanus Toxoid Vaccine Formulation with Chitosan Microspheres

R. MANIVANNAN, S. A. DHANARAJ, Y. UDAYA BHASKARA RAO, A. BALASUBRAMANIAM, N. L. GOWRISHANKAR, N. JAWAHAR AND S. JUBIE 11-15

Ionic Cross-linked Chitosan Beads for Extended Release of Ciprofloxacin: *In vitro* Characterization

A. SRINATHA, J. K. PANDIT AND S. SINGH 16-21

Design and Optimization of Diclofenac Sodium Controlled Release Solid Dispersions by Response Surface Methodology

H. N. SHIVAKUMAR, B. G. DESAI AND G. DESHMUKH 22-30

Evaluation of Free Radical Scavenging Activity of an Ayurvedic Formulation, *Panchvalkala*

SHEETAL ANANDJIWALA, M. S. BAGUL, M. PARABIA AND M. RAJANI 31-35

Validation of Different Methods of Preparation of *Adhatoda vasica* Leaf Juice by Quantification of Total Alkaloids and Vasicine

S. SONI, SHEETAL ANANDJIWALA, G. PATEL AND M. RAJANI 36-42

Formulation and Characterization of Mucoadhesive Buccal Films of Glipizide

MONA SEMALTY, A. SEMALTY AND G. KUMAR 43-48

Synthesis, Antimicrobial and Anti-inflammatory Activity of 2,5-Disubstituted-1,3,4-oxadiazoles

G. NAGALAKSHMI 49-55

Ascorbic Acid Inhibits Development of Tolerance and Dependence to Opiates in Mice: Possible Glutamatergic or Dopaminergic Modulation

S. K. KULKARNI, C. DESHPANDE AND A. DHIR 56-60

Design and *In Vitro* Characterization of Buccoadhesive Drug Delivery System of Insulin

J. SAHNI, S. RAJ, F. J. AHMAD AND R. K. KHAR 61-65

Development and Evaluation of a Chloramphenicol Hypertonic Ophthalmic Solution

A. V. JITHAN, C. KRISHNA MOHAN, AND M. VIMALADEVI 66-70

Optimization of Fast Dissolving Etoricoxib Tablets Prepared by Sublimation Technique

D. M. PATEL AND M. M. PATEL 71-76

Furosemide-loaded Alginate Microspheres Prepared by Ionic Cross-linking Technique: Morphology and Release Characteristics

M. K. DAS AND P. C. SENAPATI 77-84

SHORT COMMUNICATIONS

Isolation of Liver Aldehyde Oxidase Containing Fractions from Different Animals and Determination of Kinetic Parameters for Benzaldehyde

R. S. KADAM AND K. R. IYER 85-88

Microwave-Induced Synthesis of Schiff Bases of Amino-thiazolyl Bromocoumarins as Antibacterials

K. N. VENUGOPALA AND B. S. JAYASHREE 88-91

In vitro Antiviral Activity of some Novel Isatin Derivatives against HCV and SARS-CoV Viruses

P. SELVAM, N. MURGESH, M. CHANDRAMOHAN, E. DE CLERCQ, E. KEYAERTS, L. VIJGEN, P. MAES, J. NEYTS AND M. V. RANST 91-94

Physicochemical and Pharmacokinetic Parameters in Drug Selection and Loading for Transdermal Drug Delivery

N. S. CHANDRASHEKAR AND R. H. SHOBHA RANI 94-96

HPLC Estimation of berberine in *Tinospora cordifolia* and *Tinospora sinensis*

G. V. SRINIVASAN, K. P. UNNIKRISHNAN, A. B. REMA SHREE AND INDIRA BALACHANDRAN 96-99

Parenteral Formulation of Zopiclone

P. V. SWAMY, P. SUSHMA, G. CHIRAG, K. PRASAD, M. YOUNUS ALI AND S. A. RAJU 99-102

Simultaneous Spectrophotometric Determination of Lansoprazole and Domperidone in Capsule Dosage Form

A. P. SHERJE, A. V. KASTURE, K. N. GUJAR AND P. G. YEOLE 102-105

Novel 2-Pyrazoline Derivatives as Potential Antibacterial and Antifungal Agents

SUVARNA KINI AND A. M. GANDHI 105-108

Spectrophotometric Estimation of Ethamsylate and Mefenamic Acid from a Binary Mixture by Dual Wavelength and Simultaneous Equation Methods

ANJU GOYAL AND I. SINGHVI 108-111

Novel Colon Targeted Drug Delivery System Using Natural Polymers

V. RAVI, T. M. PRAMOD KUMAR AND SIDDARAMAIAH 111-113

Effect of Some Clinically Used Proteolytic Enzymes on Inflammation in Rats

A. H. M. VISWANATHA SWAMY AND P. A. PATIL 114-117

Synthesis and Pharmacological Evaluation of (6-Substituted 4-Oxo-4H-chromene-3 yl) methyl N-substituted Aminoacetates

ASMITA GAJBHIYE, V. MALLAREDDY AND G. ACHAI AH 118-120

Development and *In Vitro* Evaluation of Buccoadhesive Tablets of Metoprolol Tartrate

P. D. NAKHAT, A. A. KONDAWAR, L. G. RATHI AND P. G. YEOLE 121-124

RP-HPLC Estimation of Venlafaxine Hydrochloride in Tablet Dosage Forms

S. L. BALDANIA, K. K. BHATT, R. S. MEHTA, D. A. SHAH AND TEJAL R. GANDHI 124-128

Simultaneous Estimation of Esomeprazole and Domperidone by UV Spectrophotometric Method

S. LAKSHMANA PRABU, A. SHIRWAIKAR, ANNIE SHIRWAIKAR, C. DINESH KUMAR, A. JOSEPH AND R. KUMAR 128-131

In Vitro Anthelmintic Activity of *Baliospermum montanum* Muell. Arg roots

R. G. MALI AND R. R. WADEKAR 131-133

REFEREES FOR INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES DURING 2006 & 2007

134-134

Ionic Cross-linked Chitosan Beads for Extended Release of Ciprofloxacin: *In vitro* Characterization

A. SRINATHA*, J. K. PANDIT AND S. SINGH

Department of Pharmaceutics, Institute of Technology, Banaras Hindu University, Varanasi - 221 005, India

Srinatha, *et al.*: Ionic Cross-linked Chitosan Beads

Chitosan beads loaded with ciprofloxacin hydrochloride were fabricated by ionic cross-linking with sodium tripolyphosphate. The beads showed an excellent water retention property. The degradation of fabricated beads was influenced by the pH of test medium. High drug load was achieved within the bead with a short curing time. Drug release was high in acidic medium (pH 1.2) vis-à-vis intestinal medium (pH 7.4). Ciprofloxacin hydrochloride release increased with an increasing concentration of ciprofloxacin and decreasing proportion of chitosan. Drug release followed both first-order and Higuchi's root time kinetics showing non-Fickian release mechanism.

Key words: Beads, chitosan, ciprofloxacin, ionic cross-linking, tripolyphosphate

An ideal drug delivery system should release the drug in the right body compartment at a rate required for a specific treatment. Multiple unit solid dosage forms distribute the drug load more uniformly in the gastrointestinal tract with the aim to reduce local irritation^{1,2}. Chitosan, a naturally occurring polysaccharides, has received major attention in drug delivery systems. It is biocompatible and non-toxic. Chitosan is a weak cationic polysaccharide composed of [a (1→4) 2-amino-2-deoxy-β-D-glucan] obtained by the alkaline deacetylation of chitin. Chitosan spheres are usually prepared by precipitation³, anionic cross-linking⁴, chemical cross-linking⁵, thermal cross-linking⁶, co-acervation⁷ and emulsification ionic-gelation⁸ methods.

Ciprofloxacin, a fluoroquinolone was used as the model drug for the study. It has high bactericidal activity against uropathogens and in the treatment of urinary tract infections with a biological half-life of 4 h. It is advised in complicated intra-abdominal infections (in combination with metronidazole), infectious diarrhoea, typhoid fever (enteric fever), and uncomplicated cervical and urethral gonorrhoea. Ciprofloxacin is beneficial in treatment of mild to moderate Crohn's disease and in maintenance of remission⁹, and is the first line of treatment in treating gastrointestinal anthrax caused by *B. anthracis*¹⁰ where the death range is 25-60%¹¹. Extended-release

formulation of ciprofloxacin provides systemic drug exposure comparable with that achieved with twice-daily administration of conventional, immediate-release ciprofloxacin, while also attaining higher maximum plasma concentrations with less inter-patient variability¹².

The aim of the present investigation was to evaluate the factors influencing the physical properties of the chitosan beads. The study involved characterization of water uptake of the beads, its behaviour in acidic and alkaline media, and influence of formulation and study variables on the drug release.

MATERIALS AND METHODS

Ciprofloxacin hydrochloride was a generous gift of M/s Dr. Reddy's Laboratories (Hyderabad, India). Chitosan (Mol. wt. 2×10^5 , degree of deacetylation 82-88%) was obtained from M/s Kraeber Gmbh and Co (Ellerbek, Germany). Sodium tripolyphosphate (TPP) was procured from S. D. Fine Chemicals (Mumbai, India). All other reagents were of analytical grade and used as received.

Preparation of chitosan beads:

Chitosan beads were prepared by the ionic cross-linking as described by Bodemier *et al.*⁷ with minor modifications. Briefly, chitosan was dissolved in acetic acid (2% v/v) and stirred for 6-7 h on a magnetic stirrer (Remi Equipments, Mumbai). Weighed amount of ciprofloxacin HCl (Table 1) was added to the

*For correspondence

E-mail: asrinatha@yahoo.com.

TABLE 1: FORMULATION COMPOSITIONS, PHYSICAL AND RELEASE CHARACTERISTICS OF THE FABRICATED BEADS

Batch	Chitosan (% w/v)	Ciprofloxacin (% w/v)	TPP (% w/v)	Wet bead size (mm)	Dry bead size (mm)	IE (%)	Release exponent (n)
CB1	2	1	1	2.21 ± 0.32	0.61 ± 0.05	67.30 ± 2.34	0.51
CB2	2	1	2	2.23 ± 0.19	0.60 ± 0.09	67.21 ± 1.95	0.53
CB3	2	1	3	2.22 ± 0.09	0.62 ± 0.14	69.08 ± 3.11	0.53
CB4	2	1	4	2.23 ± 0.17	0.61 ± 0.08	68.70 ± 1.61	0.58
CB5	1	1	2	2.08 ± 0.51	0.65 ± 0.15	60.53 ± 2.09	0.51
CB6	3	1	2	2.31 ± 0.24	0.70 ± 0.03	73.67 ± 2.44	0.58
CB7	2	0.5	2	2.11 ± 0.21	0.69 ± 0.11	75.80 ± 2.39	0.59
CB8	2	2	2	2.24 ± 0.28	0.68 ± 0.08	64.42 ± 3.10	0.47

IE- Incorporation efficiency, calculated from the percentage ratio of actual drug concentration in the bead to theoretical drug concentration

polymeric solution and stirred on a magnetic stirrer for 2 h, and allowed to stand till the removal of the entrapped air bubbles. The pH of the drug-chitosan solution was adjusted to pH 4-4.5 with dilute alkali solution (0.1 M, NaOH). Chitosan solution containing drug was added dropwise using a syringe fitted with a flat-end needle (23G, 0.7 mm id) into sodium tripolyphosphate solution (1-4% w/v, pH 5, 60°). Beads were left for 20-30 min, unless otherwise specified, and after curing, were collected by filtration, washed twice with distilled water and dried at 50° for 4 h and then at room temperature (25°) for 12 h.

Particle size determination:

The particle size of the prepared beads in a sample was measured with an optical micrometer fitted with a calibrated eye piece. The mean of 100 beads was noted as particle size. The sizes of both wet and dried beads were measured. All readings are average of three trials ± SD.

Determination of encapsulation efficiency:

About 50 mg of the beads were crushed in a glass mortar and digested in 0.1 N hydrochloric acid (pH 1.2) for 24 h in a graduated flask. The solution was filtered through a G-2 filter and an aliquot was used to assay for drug content spectrophotometrically (Jasco 7800, Japan) at 276 nm against a suitable blank. The encapsulation efficiency was calculated by expressing the actual entrapment level divided by the theoretical entrapment level, as a percentage. The values are average of three trials ± SD.

Surface morphology of the beads:

The surface morphology images were obtained by scanning bead surface on an electron microscope (SEM, Philips XL20, Holland) under vacuum. Beads were mounted on brass stubs using silver paste and scanned under vacuum at the required magnification at room temperature.

Water uptake studies:

Water uptake capacity of the beads was determined in 0.1 N HCl (pH 1.2) and pH 7.4. A weighed quantity of beads (100 mg) was immersed in SGF (0.1 N HCl, pH 1.2) and SIF (pH 7.4), and at regular intervals of time, the beads were reweighed after carefully wiping off excess of liquid with a tissue paper. The water uptake was determined from the expression; $(W_t - W_0)/W_0$, where, W_t and W_0 are the weight of the beads at time 't' and under dry state, respectively.

In vitro degradation study:

In vitro degradation of beads was investigated in pH 1.2 and 7.4. Beads (100 mg) were placed in basket of USP-XXIII dissolution apparatus containing 900 ml of respective media at 50 rpm. At regular intervals beads were removed, excess liquid was wiped off, and oven dried at 80° till constant weight. The mass loss of the beads was calculated from the dry weights measured at the beginning and predetermined time intervals.

In vitro drug release studies:

In vitro release of ciprofloxacin from the beads was performed in USP XXIII dissolution apparatus II with a paddle speed of 50 rpm. The dissolution medium was 900 ml of SGF without enzyme (0.1 N HCl, pH 1.2) for first 2 h and subsequently rest of the release study was performed in SIF (phosphate buffer, pH 7.4) at $37 \pm 0.2^\circ$. At regular time intervals, 5 ml aliquot was withdrawn and replenished with an equal volume of fresh dissolution medium. The drug content in the aliquot was assayed spectrophotometrically at 276 nm (Jasco 7800, Japan). A study was performed concurrently with placebo beads to record for any interference by the bead components.

For analyzing drug release kinetics, *in vitro* release data were fitted to; zero-order equation, $Q_t = Q_0 + K_0 t$; first-order equation^{13,14} $Q_t = Q_0 e^{-Kt}$; and Higuchi's¹⁵

square root model $Q_t = K_H \sqrt{t}$, where, Q_t is the amount of drug released in time 't', Q_0 is the initial amount of drug in dissolution medium, and K_0 , K and K_H are respective release constants. The mechanism of drug release was further analysed using the Korsmeyer-Peppas power law^{16,17} $M_t/M_\infty = Kt^n$, where, M_t/M_∞ is the fraction of drug released in time 't', K is structural and geometric constant, and n is the release exponent.

Statistical analysis:

All data were analysed by Student's t-test and one-way ANOVA, wherever necessary, using Sigma Stat 2.0 (Jandel Scientific corporation, USA) to determine the statistical difference in the results. A probability value $p < 0.05$ was considered statistically significant.

RESULTS AND DISCUSSION

Chitosan, being a multivalent cationic polysaccharide forms gel with suitable anions. Sodium tripolyphosphate was used in this study as a counter ion for chitosan. Chitosan is insoluble in alkaline and neutral pH, but soluble in acidic solvents. The amine groups undergo protonation in acidic environment that increases its solubility in acidic solutions¹⁸. The protonated amine groups interact with phosphate ions, provided by TPP, either by intermolecular or intramolecular linkage. On addition of chitosan solution to TPP solution, the acetic acid of chitosan solution is rapidly neutralized with the ingress of coagulation fluid which causes decrease in pH within the beads⁷. Simultaneously, the amine group of chitosan interacts with phosphate ions of tripolyphosphate solution. Both processes lead to precipitation of chitosan with simultaneous entrapment of added ciprofloxacin within its matrix.

The size of both wet and dry beads were determined and recorded (Table 1). Wet beads were in the range of $2.08 \pm 0.51 - 2.31 \pm 0.24$ mm. On drying, the size of beads decreased significantly ($p < 0.05$) to $0.60 \pm 0.09 - 0.70 \pm 0.03$ mm. The large size of wet beads suggests of high swelling and water retention ability of the beads. Bead size increased markedly with an increase in the drug loading. SEM imaging revealed that beads (without ciprofloxacin) were spherical, with rough and wrinkled surface (fig. 1a). However, the shape of the ciprofloxacin loaded beads was nearly spherical but with non-uniform surfaces (fig. 1b).




Fig. 1: Surface SEM images of the prepared beads. (a) placebo chitosan beads and (b) Ciprofloxacin-loaded beads (batch CB2).

Encapsulation efficiency of the multi-unit systems is an important parameter. As the curing occurs in aqueous solution, it is likely that a part of the drug would leach into coagulation fluid. The curing duration had an impact on the entrapment efficiency of fabricated beads. Ciprofloxacin entrapment decreases as the curing time increases. Highest drug entrapment, $90 \pm 1.96\%$, was achieved at a short curing time (10 min). However, this time was insufficient for complete gelation of chitosan⁷. The minimum curing time determined for complete gelation of chitosan beads with satisfactory encapsulation was 20 min. In coagulation fluid, acetic acid diffuses into the external phase and the TPP solution diffuse into the droplets. During this process, the added drug diffuses to the external phase, hence, longer retention of the beads in the coagulation fluid lowers drug entrapment. The order of encapsulation was 90 ± 1.96 , 69.46 ± 2.86 , 61.85 ± 2.45 , 40.02 ± 2.01 and $27.93 \pm 1.94\%$ in 10, 20, 30, 45 and 60 min, respectively.

Water uptake capacity of the beads was determined in two different media and varied with pH of the media used. Higher water uptake was observed in simulated gastric fluid than in simulated intestinal fluid. The phenomenon is expected, based on the pH dependent solubility of chitosan. Other than pH of the media, the water uptake of bead was influenced by pH of TPP solution. The swelling ratio was higher for chitosan beads prepared in TPP solution at pH 5.0 than when the pH was 8.5. Amongst the two media used, swelling ratio was high at pH 1.2 in comparison to 7.4 which is in line with the earlier report by Mi *et al.*¹⁹.

The degradation rate of the beads depended on the pH of test medium. In acidic medium (0.1 N HCl, pH 1.2) the degradation was faster with $>50\%$ mass loss in ~ 5.5 h. Conversely, the degradation was found to be negligible at pH 7.4. The faster degradation in SGF was in contrast with the observations of

Durkut *et al.*²⁰, wherein the complete degradation was achieved in 6 months. The observed faster degradation could be due to high acid solubility of ciprofloxacin, which caused pores in the matrix leading to easy ingress of SGF and subsequent degradation.

The release of ciprofloxacin in two different media (pH 1.2 and 7.4) is shown in fig. 2. The percent of drug released at pH 1.2 was higher in comparison to that at pH 7.4 exhibiting pH-sensitivity of the beads. At the end of 4 h, 98% of drug load was depleted from CB1 (TPP- 1% w/v) in SGF (0.1 N HCl, pH 1.2), in comparison to 70% in SIF (pH 7.4). The result was similar for beads prepared with higher concentration of TPP with a release of ~70% for CB4 (TPP- 4% w/v) at pH 1.2 and ~50% at pH 7.4. The results indicate significant ($p < 0.05$) influence of pH of dissolution medium on drug release. The faster drug release at pH 1.2 and sustained release at pH 7.4 corroborates with the results of water uptake and degradation studies. An initial burst release of drug was observed from all the batches that can be attributed to two reasons: the leaching of drug on the bead outer surface and faster ingress of dissolution medium and subsequent diffusion of drug. However, on changing the pH from lower to higher level, the drug release slowed (fig. 3). At the end of 8 h, 93.2% of drug was released from CB2 in comparison to 85.4% in 4 h at pH 1.2. Similar pattern was observed in the case of CB3 and CB4. The exception being CB1, which even with pH change released 96% drug in 6 h (the corresponding release in pH 1.2 was 96.3% in 4 h). The results are in contrast to the earlier report of poor pH-responsive drug release of riboflavin²¹, but similar to other researchers^{22,23}. The pH-responsive release can best be explained based on charge density on the beads¹⁹, which is an important




Fig. 2: Effect of pH of dissolution medium on *in vitro* ciprofloxacin release. Drug release profiles of CB1 (—●—), CB2 (—○—), CB3 (—▼—) and CB4 (—△—) in (a) SGF (0.1 N HCl, pH 1.2) (b) pH 7.4.

factor in electrostatic interaction and depends on solution pH. In SGF, protonation of phosphate ions causes hydrogen bond to break, leading to weaker electrostatic interaction. This caused swelling and higher release in SGF, while in SIF stronger attractive force between phosphate ions and chitosan caused slower release of drug. The change in pH of dissolution medium caused swelling (2 h, pH 1.2) and later deswelling (in pH 7.4) leading to bimodal drug release.

Sodium tripolyphosphate was used at four concentrations to investigate its effect on the release profile. Drug release from hydrogels is controlled by the degree of cross-linking²⁴. The release of ciprofloxacin from the beads decreased with increased cross-linking agent concentration. However, except for 1% w/v TPP, the drug release did not vary significantly ($p > 0.05$). The primary reason for this observation is, increasing the cross-linking density reduces swelling of the beads hindering drug release⁷.

The effect of pH of TPP solution on drug release is shown in fig. 4. Ciprofloxacin release from the beads was influenced by the pH of TPP solution. Beads prepared in original solution (pH 8.5) released ciprofloxacin faster than those prepared after adjusting the pH of TPP solution to 5.0. The pore structure of chitosan microparticle was modified by the change in




Fig. 3: Effect of change of pH of dissolution fluid on drug release from the beads.

In vitro drug release was tested for first two hours in pH 1.2 (0.1 N HCl) and changed to pH 7.4. CB1 (—●—), CB2 (—○—), CB3 (—▼—), CB4 (—△—).

the pH of TPP solution²⁵. At higher pH open porous structure with low density was reported by Ko *et al.*²⁶. The ionization of amine group on chitosan decreases with increasing pH proceeding to weaker cross-linking density. These reasons attribute to the faster release of ciprofloxacin from beads prepared in TPP solution at pH 8.5.

The release of ciprofloxacin depends on its concentration in the bead and chitosan (fig. 5). Fast and complete drug release was observed from CB5




Fig. 4: Effect of pH of coagulation fluid on drug release. Beads were fabricated with coagulation fluid (sodium tripolyphosphate solution) at pH 5 (—●—) and 8.5 (—○—).




Fig. 5: Influence of ciprofloxacin and chitosan concentration on *in vitro* drug release profile. Drug release profile of batches CB2 (—●—), CB5 (—○—), CB6 (—▼—), CB7 (—△—) and CB8 (—■—).

and CB8 containing equal ratio of ciprofloxacin and chitosan (1:1 drug:chitosan) in comparison to other batches. The drug release was reduced with decrease in ciprofloxacin and increase in chitosan concentration. Beads exhibited a burst release (~20% in 30 min). The diffusion of drug from the surface creates a pore in the matrix which causes a channelling effect. Incorporation of higher concentration of drug causes more pore formation leading to faster and higher drug release. This phenomenon was in contrast to the reported decrease in drug release with increasing concentration of sulphadiazine, a poorly soluble drug⁷.

The regression co-efficient (r^2) for equation $Q_t = Q_0 e^{-Kt}$ was between 0.9902 and 0.9968 for batches CB1, CB2, CB3 and CB7. This was higher than for other kinetic equations indicating that drug release followed first-order kinetics. Other fabricated batches viz., CB4, CB5, CB6 and CB8, showed higher regression coefficient (between 0.9853 and 0.9979) for Higuchi's square root equation ($Q_t = K_H \sqrt{t}$) indicating time dependent release mechanism. The release exponent (n) values (Table 1) were in the range of 0.47-0.59 suggesting drug release by a combination of diffusion and dissolution. The observed deviation from Fickian mechanism could be possibly due to higher molecular weight²⁷ of ciprofloxacin (331.4) and the polymer characteristics (solubility, pKa, tortuosity)²⁸. The fabricated beads showed good reproducibility. The process being simple can be used in the formulation of sustained release formulations. A desired release profile could be achieved by modifying a few process parameters, which are discussed above. Further studies are needed to evaluate the performance of these systems in *in vivo* and to optimize the formulation.

REFERENCES

1. Lauwo JA, Agarwal DK, Emenike IV. Some pharmaceutical studies on sustained-release co-precipitates of ampicillin trihydrate with acrylic resin (Eudragit-RS). *Drug Develop Ind Pharm* 1990;16:1375-89.
2. Bodmeier R, Chen H, Tyle P, Jarosz P. Pseudoephedrine HCl microspheres formulated into an oral suspension dosage form. *J Control Release* 1991;15:65-77.
3. Berthold A, Cremer K, Kreuter J. Preparation and characterization of chitosan microspheres as drug carrier for prednisolone sodium phosphate as model for anti-inflammatory drugs. *J Control Release* 1996;39:17-25.
4. Bodmeier R, Paerathakul O. Spherical agglomerates of water insoluble drugs. *J Pharm Sci* 1989;78:964-67.
5. Thanoo BC, Sunny MC, Jayakrishnan A. Cross-linked chitosan microspheres: Preparation and evaluation as a matrix for controlled release of pharmaceuticals. *J Pharm Pharmacol* 1992;44:283-6.

6. Orienti I, Aiedeh K, Gianasi E, Bertasi V, Zecchi V. Indomethacin loaded chitosan microspheres: Correlation between the erosion process and release kinetics. *J Microencapsul* 1996;13:463-72.
7. Bodmeier R, Oh KH, Parmar Y. Preparation and evaluation of drug containing chitosan beads. *Drug Develop Ind Pharm* 1989;15:1475-94.
8. Singla AK, Dhawan S. Nifedipine loaded chitosan microspheres prepared by emulsification and phase separation. *Biotech Histochem* 2003;78:243-54.
9. Knutson D, Greenberg G, Cronau H. Management of Chron's disease: A practical approach. *Am Fam Physician* 2003;68:707-14.
10. Binkley CE, Cinti S, Simeone DM, Colletti LM. Bacillus anthracis as an agent of bioterrorism: A review emphasizing surgical treatment. *Ann Surg* 2002;236:9-16.
11. Pile JC, Malone JD, Eitzen EM, Friedlander AM. Anthrax as a potential biological warfare agent. *Arch Int Med* 1998;158:429-34.
12. Blondeau JM. Current issues in the management of urinary tract infections: Extended-release ciprofloxacin as a novel treatment option. *Drugs* 2004;64:611-28.
13. Gibaldi M, Feldman S. Establishment of sink conditions in dissolution rate determinations-theoretical considerations and application to non-disintegrating dosage forms. *J Pharm Sci.* 1967;56:1238-42.
14. Wagner JG. Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules. *J Pharm Sci* 1969;58:1253-7.
15. Higuchi T. Mechanism of sustained action medication: Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. *J Pharm Sci* 1963;52:1145-9.
16. Korsmeyer RW, Gurny R, Doelker EM, Buri P, Peppas NA. Mechanism of solute release from porous hydrophilic matrices. *Int J Pharm* 1983;15:25-35.
17. Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. *Pharm Acta Helv* 1985;60:110-1.
18. Hejazi R, Amiji M. Chitosan based gastrointestinal delivery systems. *J Control Release* 2003;89:151-65.
19. Mi FL, Sung HW, Shyu SS, Su CC, Peng CK. Synthesis and characterization of biodegradable TPP/ genipin co-crosslinked chitosan gel beads. *Polymer* 2003;24:6521-30.
20. Durkut S, Elcin ME, Elcin AE. Biodegradation of chitosan-tripolyphosphate beads: *In vitro* and *in vivo* studies. *Artif Cells Blood Substit Biotechnol* 2006;34:263-76.
21. Shu XZ, Zhu KJ. Controlled drug release properties of ionically cross-linked chitosan beads: The influence of anion structure. *Int J Pharm* 2002;233:217-25.
22. Shirashi S, Imai T, Otagiri M. Controlled release of indomethacin by chitosan-polyelectrolyte complex: Optimization and *in vivo/in vitro* evaluation. *J Control Release* 1993;25:217-25.
23. Remunan-Lopez C, Bodmeier R. Mechanical, water uptake and permeability properties of cross-linked chitosan glutamate and alginate films. *J Control Release* 1997;44:215-25.
24. Korsmeyer RW, Peppas NA. Effect of morphology of hydrophilic polymer matrices on the diffusion and release of water soluble drugs. *J Membr Sci* 1981;9:211-27.
25. Mi FL, Shyu SS, Lee ST, Wong TB. Kinetic study of chitosan-tripolyphosphate complex reaction and acid resistive properties of the chitosan-tripolyphosphate gel beads prepared by in-liquid curing method. *J Polym Sci Polym Phys* 1999;37:1551-64.
26. Ko JA, Park HJ, Hwang SJ, Park JB, Lee JS. Preparation and characterization of chitosan microparticles intended for controlled drug delivery. *Int J Pharm* 2002;249:165-74.
27. Sheu MT, Chou HL, Kao CC, Liu CH, Sokolski TD. Dissolution of diclofenac sodium from matrix tablet. *Int J Pharm* 1992;85:57-63.
28. Reza S, Quadir MA, Haider SS. Comparative evaluation of plastic, hydrophobic, and hydrophilic polymers as matrices for controlled release drug delivery. *J Pharm Pharmaceut Sci* 2003;6:282-91.

Accepted 7 January 2008
Revised 11 October 2007
Received 25 January 2007
Indian J. Pharm. Sci., 2008, 70 (1): 16-21